Research effects
Mazdutide is an oxyntomodulin analog and a dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Its core mechanism synergistically suppresses appetite and delays gastric emptying via GLP-1R activation, while GCGR activation promotes hepatic fatty acid oxidation and energy expenditure, achieving potent weight loss and metabolic improvements. In a Phase 3 trial in Chinese adults with obesity, the 9 mg dose achieved a mean weight reduction of 16.65% at 60 weeks, with 84.3% of participants achieving ≥5% weight loss. Mechanistic studies demonstrate superior efficacy over semaglutide monotherapy in reducing hepatic fat accumulation, primarily through activating oxidative phosphorylation and fatty acid degradation pathways. Uric acid-lowering and renal function-improving effects have also been observed in animal models, involving regulation of renal transporter expression. Adverse events are primarily mild-to-moderate gastrointestinal reactions.
